|
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Clinical research trials and Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery. Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery clinical trial. Subjects frequently get the best healthcare possible for their Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
For Condition: adenocarcinoma of the lung,large cell lung cancer,stage 2 non-small cell lung cancer,stage 3A non-small cell lung cancer,stage 1 non-small cell lung cancer,squamous cell lung cancer
Status: Recruiting
Sponsor(s): American College of Surgeons , National Cancer Institute (NCI)
Synopsis: RATIONALE: Prognostic testing for early signs of metastases may help doctors detect metastases early and plan more effective treatment. PURPOSE: Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I, stage II, or stage III non-small cell lung cancer that can be removed by surgery.
Details: OBJECTIVES: - Determine the relationship between three indicators of occult metastases (cytological examination of pleural lavage, immunohistochemistry (IHC) assay of lymph nodes, and IHC assay of rib bone marrow) and survival of patients with resectable non-small cell lung cancer. - Determine the relationship between these indicators and conventional histology. - Model survival considering the indicators and other patient attributes that are of prime prognostic significance. - Determine the relationships between the indicators and the site of first recurrence in these patients. - Determine the prevalence of the indicators in these patients. - Determine the relationships between the indicators and disease free survival in these patients. OUTLINE: All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed. Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods. Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years. PROJECTED ACCRUAL: A total of 1200 patients will be accrued for this study over 4 years.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven stage I, IIA, IIB, or IIIA non-small cell lung cancer (NSCLC) - Histological confirmation may be preoperative or intraoperative - Clinically resectable disease - If preoperative mediastinoscopy performed, N1 or N2 disease eligible - Squamous cell, adenocarcinoma, or large cell - Thoracotomy with intention of complete resection planned - Pneumonectomy, bilobectomy, lobectomy, or anatomic segmentectomy, with or without sleeve resection - No pleural effusion PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 OR - Zubrod 0-2 Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Pulmonary: - See Disease Characteristics Other: - Medically fit for surgery - No other malignancies within the past 5 years except curatively treated malignancies with low risk of recurrence PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy for NSCLC - Adjuvant chemotherapy allowed Endocrine therapy: - Not specified Radiotherapy: - No prior radiotherapy for NSCLC - Adjuvant radiotherapy allowed Surgery: - See Disease Characteristics - At least 5 years since prior ipsilateral thoracotomy or thoracostomy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobbinCohen, Study Chair, University of Southern California, Healthcare Consultation Center
Veterans Affairs Medical Center - Seattle *Recruiting*
Seattle, Washington, 98108
United States
Recruiting Douglas Wood 206-685-3228
USC/Norris Comprehensive Cancer Center and Hospital *Recruiting*
Los Angeles, California, 90033-0804
United States
Recruiting Robbin Cohen 323-865-3000
Mobile Infirmary Medical Center *Recruiting*
Mobile, Alabama, 36640-0460
United States
Recruiting Gaylord Walker 251-435-2400
Western Pennsylvania Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15224
United States
Recruiting Robert Keenan 412-359-6202
UCSF Comprehensive Cancer Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting David Jablons 415-885-3882
McLaren Regional Cancer Center *Recruiting*
Flint, Michigan, 48432
United States
Recruiting Joyce Strohl 810-732-8322
University of California Davis Cancer Center *Recruiting*
Sacramento, California, 95817
United States
Recruiting Richard Bold 916-734-7269
University of Wisconsin Comprehensive Cancer Center *Recruiting*
Madison, Wisconsin, 53792-7375
United States
Recruiting John Niederhuber 608-265-5212
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4009
United States
Recruiting Raphael Pollock 713-792-6928
Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital *Recruiting*
Ft. Lauderdale, Florida, 33308
United States
Recruiting Leonard Seigel 954-267-7700
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Valerie Rusch 212-639-5873
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus *Recruiting*
Seattle, Washington, 98104
United States
Recruiting Ralph Aye 206-682-4790
West Virginia University Hospitals *Recruiting*
Morgantown, West Virginia, 26506-9300
United States
Recruiting Geoffrey Graeber 304-293-4180
Veterans Affairs Medical Center - Omaha *Recruiting*
Omaha, Nebraska, 68105
United States
Recruiting Robert Fitzgibbons 402-280-4503
Medical College of Wisconsin Cancer Center *Recruiting*
Milwaukee, Wisconsin, 53226
United States
Recruiting Mario Gasparri 414-805-4450
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111-2497
United States
Recruiting Elin Sigurdson 215-728-3519
Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus *Recruiting*
Nashville, Tennessee, 37212
United States
Recruiting John Roberts 615-327-4751
Alexian Brothers Medical Center *Recruiting*
Elk Grove Village, Illinois, 60007
United States
Recruiting Thomas Hinkamp 847-981-6087
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center *Recruiting*
Nashville, Tennessee, 37232-6838
United States
Recruiting John Roberts 615-936-1782
Hurley Medical Center *Recruiting*
Flint, Michigan, 48503
United States
Recruiting Joyce Strohl 810-732-8322
Providence Cancer Center at Providence Portland Medical Center *Recruiting*
Portland, Oregon, 97213-2967
United States
Recruiting John Handy 503-215-2300
University Hospital at State University of New York - Upstate Medical University *Recruiting*
Syracuse, New York, 13210
United States
Recruiting Leslie Kohman 315-464-6321
University Cancer Center at University of Washington Medical Center *Recruiting*
Seattle, Washington, 98195-6310
United States
Recruiting Douglas Wood 206-685-3228
Westmoreland Regional Hospital *Recruiting*
Greensburg, Pennsylvania, 15601-2282
United States
Recruiting Rodney Landreneau 412-359-6412
William Beaumont Hospital - Royal Oak *Recruiting*
Royal Oak, Michigan, 48073
United States
Recruiting Gary Chmielewski 248-551-0669
Abramson Cancer Center at University of Pennsylvania Medical Center *Recruiting*
Philadelphia, Pennsylvania, 19104-4283
United States
Recruiting Douglas Fraker 215-662-7866
Bayfront Medical Center *Recruiting*
Saint Petersburg, Florida, 33701
United States
Recruiting Robert Reichert 727-821-1221
Barnes-Jewish Hospital *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Bryan Meyers 314-362-8598
Jewish Hospital *Recruiting*
Louisville, Kentucky, 40202-1886
United States
Recruiting Roy Bowling 502-589-3173
St. John's Hospital *Recruiting*
Springfield, Illinois, 62701
United States
Recruiting Stephen Hazelrigg 217-545-8875
Creighton University School of Medicine *Recruiting*
Omaha, Nebraska, 68131
United States
Recruiting Robert Fitzgibbons 402-280-4503
Providence Hospital - Mobile AL *Recruiting*
Mobile, Alabama, 36685
United States
Recruiting Gaylord Walker 251-433-5557
Roswell Park Cancer Institute *Recruiting*
Buffalo, New York, 14263-0001
United States
Recruiting Timothy Anderson 716-845-5873
Veterans Affairs Medical Center - Milwaukee (Zablocki) *Recruiting*
Milwaukee, Wisconsin, 53295
United States
Recruiting Mario Gasparri 414-456-6904
Lankenau Cancer Center at Lankenau Hospital *Recruiting*
Wynnewood, Pennsylvania, 19096
United States
Recruiting Ned Carp 610-642-1908
Long Island Cancer Center at Stony Brook University Hospital *Recruiting*
Stony Brook, New York, 11790-8191
United States
Recruiting Thomas Bilfinger 631-444-1820
Holden Comprehensive Cancer Center at University of Iowa *Recruiting*
Iowa City, Iowa, 52242-1062
United States
Recruiting Kemp Kernstine 319-356-3407
Jameson Memorial Hospital *Recruiting*
New Castle, Pennsylvania, 16105
United States
Recruiting Robert Keenan 412-359-6202
Comprehensive Cancer Center at Wake Forest University *Recruiting*
Winston Salem, North Carolina, 27157-1082
United States
Recruiting Edward Levine 336-716-4276
MetroHealth Medical Center *Recruiting*
Cleveland, Ohio, 44109
United States
Recruiting Bruce Averbook 216-778-4795
Toronto General Hospital *Recruiting*
Toronto, Ontario, M5G 2C4
Canada
Recruiting Gail Darling 416-340-3121
Ireland Cancer Center *Recruiting*
Cleveland, Ohio, 44106-5065
United States
Recruiting Bruce Averbook 216-778-4795
Cancer Institute at Oregon Health and Science University *Recruiting*
Portland, Oregon, 97239
United States
Recruiting Kevin Billingsley 503-494-5501
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19107-5541
United States
Recruiting Ronald Weigel 215-955-0526
Cancer Care Ontario-London Regional Cancer Centre *Recruiting*
London, Ontario, N6A 4L6
Canada
Recruiting Richard Inculet 519-667-6679
St. Clair Memorial Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15243-1899
United States
Recruiting Rodney Landreneau 412-359-6412
University of Colorado Health Sciences Center - Denver *Recruiting*
Denver, Colorado, 80262
United States
Recruiting John Mitchell 303-315-4556
Huntington Cancer Center at Huntington Hospital *Recruiting*
Pasadena, California, 91105
United States
Recruiting Robbin Cohen 323-442-5850
Southern Illinois University School of Medicine *Recruiting*
Springfield, Illinois, 62702
United States
Recruiting Stephen Hazelrigg 217-545-8875
Saint Thomas Hospital *Recruiting*
Nashville, Tennessee, 37205
United States
Recruiting Jonathan Nesbitt 615-385-4781
LDS Hospital *Recruiting*
Salt Lake City, Utah, 84143
United States
Recruiting Michael Collins 801-321-2260
University of Chicago Cancer Research Center *Recruiting*
Chicago, Illinois, 60637-1470
United States
Recruiting Mark Ferguson 773-702-3551
Cottonwood Hospital Medical Center *Recruiting*
Murray, Utah, 84107
United States
Recruiting Michael Collins 801-321-2260
Cancer Center at the University of Virginia *Recruiting*
Charlottesville, Virginia, 22908
United States
Recruiting David Jones 434-243-6443
Allegheny General Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15212-4772
United States
Recruiting Robert Keenan 412-359-6202
James P. Wilmot Cancer Center at University of Rochester Medical Center *Recruiting*
Rochester, New York, 14642
United States
Recruiting David Johnstone 585-275-1509
Temple University Hospital *Recruiting*
Philadelphia, Pennsylvania, 19140
United States
Recruiting Arun Singhal 215-707-2685
Charles M. Barrett Cancer Center at University Hospital *Recruiting*
Cincinnati, Ohio, 45267-0558
United States
Recruiting John Howington 513-584-1391
Additional Information:
Study ID Numbers: CDR0000067072; ACOSOG-Z0040
Study Start Date:
Record last reviewed: November 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003901
Other Stage 3a Non-Small Cell Lung Cancer Studies:
1. Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Treating Patients With Stage III Non-small Cell Lung Cancer
2. Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
3. Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
4. Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
5. Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Related Studies:
Other stage 3A non-small cell lung cancer Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
|
|
|
|
|
|
|
|